CMPX · Compass Therapeutics, Inc. · Executive Compensation
$0.96
+0.10 (+12.13%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$193.41M
Shares
180.09M
Volume · Oct 5
15.83M
Avg daily vol (3M)
3.99M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | MD., Ph.D. Chief Executive Officer | $5,097,150 |
| Jonathan E. Anderman | General Counsel and Corporate Secretary | $1,427,800 |
| Barry Shin | Chief Financial Officer | $1,394,500 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Vered Bisker-Leib | Ph.D., MBA Formerly Chief Executive Officer | $6,433,665 |
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $3,093,057 |
| Barry Shin | Chief Financial Officer | $1,220,942 |
| Jonathan E. Anderman | General Counsel and Corporate Secretary | $893,635 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $4,873,206 |
| Vered Bisker-Leib | Ph.D., MBA Formerly Chief Executive Officer | $4,067,284 |
| Jonathan E. Anderman | General Counsel and Corporate Secretary | $707,948 |
| Barry Shin | Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. President of Research & Development (formerly CEO) | $2,115,185 |
| Vered Bisker-Leib | Ph.D., MBA Chief Executive Officer (formerly President and COO) | $1,724,739 |
| Susan Kalled | Chief Scientific Officer | $462,030 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $5,258,000 |
| Vered Bisker-Leib | Ph.D., MBA President and Chief Operating Officer | $4,450,000 |
| Susan Kalled | Chief Scientific Officer | $1,781,616 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Vered Bisker-Leib | Ph.D., MBA President and Chief Operating Officer | $2,571,579 |
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $2,556,793 |
| Susan Kalled | Chief Scientific Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Thomas J. Schuetz | M.D., Ph.D. Chief Executive Officer | $1,373,843 |
| Vered Bisker-Leib | Ph.D., MBA President and Chief Operating Officer | $1,055,034 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Neil Lerner | principal accounting officer | Appointed | 2024-12-10 |
| Barry Shin | Chief Financial Officer | Appointed | 2024-12-10 |
| Thomas Schuetz | President and Chief Executive Officer (Principal Executive Officer, Principal Financial and Principal Accounting Officer) | Appointed | 2024-05-28 |
| Vered Bisker-Leib | member of the Board of Directors | Resigned | 2024-05-28 |
| Vered Bisker-Leib | Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) | Resigned | 2024-05-28 |
| Vered Bisker-Leib, PhD | member of the Board | Appointed | 2024-01-09 |
| Vered Bisker-Leib, PhD | Chief Executive Officer | Appointed | 2024-01-09 |
| Richard S. Lindahl | member and chairman of the Company's Audit Committee | Appointed | 2023-04-24 |
| Richard S. Lindahl | Class III director | Appointed | 2023-04-24 |
| David Wurzer | member of the Board of Directors | Resigned | 2023-02-24 |
| David Wurzer | Class III director | Appointed | 2023-02-10 |
| Stephen Squinto, Ph.D. | member of the Board of Directors | Resigned | 2022-08-19 |